Guggenheim initiated coverage of Nautilus Biotechnology with a Buy rating and $6 price target. The analyst says the company has an innovative platform for proteome analysis and discovery applications. The company’s platform addresses the limitations of existing protein analysis technologies with high-throughput capabilities and unique discovery use cases, the analyst tells investors in a research note. The firm believes Nautilus’ technology fills a market need for new proteome analysis tools.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NAUT:
- Nautilus Biotechnology assumed with a Hold from Buy at Jefferies
- Nautilus Biotechnology’s ESG Challenge: Navigating the Rising Tide of Corporate Responsibility Standards
- Nautilus Biotechnology Reports First Quarter 2024 Financial Results
- Nautilus Biotechnology reports Q1 EPS (15c) vs (12c) last year